Immune-related diagnostic markers for benign prostatic hyperplasia and their potential as drug targets
2024

New Diagnostic Markers for Benign Prostatic Hyperplasia

Sample size: 32 publication 10 minutes Evidence: high

Author Information

Author(s): Wang YaXuan, Wang Jing, Liu Jibin, Zhu HaiXia

Primary Institution: Cancer Research Centre Nantong, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, China

Hypothesis

Can immune-related diagnostic markers improve the diagnosis and treatment of benign prostatic hyperplasia (BPH)?

Conclusion

The study identifies novel immune-related diagnostic markers for BPH and suggests their potential as drug targets.

Supporting Evidence

  • 185 differential genes were identified, including 67 up-regulated and 118 down-regulated.
  • DACH1, CACNA1D, STARD13, and RUNDC3B were identified as key diagnostic markers.
  • Molecular docking analysis showed strong binding affinities of these markers to tamsulosin and finasteride.
  • Experimental validation confirmed the expression differences of the identified genes in BPH tissues.

Takeaway

Researchers found new markers that can help doctors diagnose a common prostate problem in older men and may also help in creating new treatments.

Methodology

The study used bioinformatics analysis and machine learning techniques on datasets from the Gene Expression Omnibus to identify key diagnostic markers.

Limitations

The study primarily relies on online datasets for analysis, which may present certain limitations.

Participant Demographics

The study included 29 samples of BPH and 3 samples of normal prostate tissue.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1516362

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication